Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors
View Patent ↗A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf is beneficial, eg. cancer.
1. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of
(i) a compound of formula (I)
or a pharmaceutically acceptable salt or solvate thereof; and
(ii) a compound of formula (II)
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein compound (I) is in the form of the dimethyisulfoxide solvate.
3. The method of claim 1 , wherein compound (II) is in the form of the methanesulfonate salt.
4. The method of claim 1 , wherein the non-small cell lung cancer is BRAF V600E mutant non-small cell lung cancer.
5. A method of treating non-small cell lung cancer in a human in need thereof which comprises the administration of a therapeutically effective amount of
(i) a compound of formula (I)
or a pharmaceutically acceptable salt thereof; and
(ii) a compound of formula (II)
or a pharmaceutically acceptable salt thereof.